Resource Summary Report

Generated by RRID on Sep 2, 2026

SU-DHL-2

RRID:CVCL_9550
Type: Cell Line

Proper Citation

RRID:CVCL_9550

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_9550

Proper Citation: RRID:CVCL_9550

Description: Cell line SU-DHL-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma activated B-cell type

Defining Citation: PMID:83902, PMID:214220, PMID:371794, PMID:3881165, PMID:4140017, PMID:8547074, PMID:15356658, PMID:21179087

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-2

Synonyms: SUDHL2, SUDHL-2, Su-DHL-2, SU-DHL2, SuDHL 2, Stanford University-Diffuse Histiocytic Lymphoma-2, DHL-2

Cross References: BTO:BTO_0006463, EFO:EFO_0007611, ATCC:CRL-2956, ChEMBL-Cells:CHEMBL4523529, ChEMBL-Targets:CHEMBL4523560, Cosmic:1289989, Cosmic:1486588, Cosmic:1517653, Cosmic:1550339, Cosmic:1636686, Cosmic:2361374, DSMZ:ACC-902, DSMZCellDive:ACC-902, ENCODE:ENCBS354PZC, ENCODE:ENCBS446LEC, ENCODE:ENCBS621PAH, ENCODE:ENCBS775VGT, GEO:GSM1374905, PubChem_Cell_line:CVCL_9550, Wikidata:Q54970715

ID: CVCL_9550

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260830T000034+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-2.

No alerts have been found for SU-DHL-2.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Mamidi MK, et al. (2025) Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(3), 588.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Ding Y, et al. (2024) A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma. Scientific reports, 14(1), 21184.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular cell, 81(10), 2094.

Dietz A, et al. (2020) Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. International journal of cancer, 147(5), 1485.

Zhang J, et al. (2020) Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. Cell chemical biology, 27(12), 1500.